Loading...
Systematic review of dasatinib in chronic myeloid leukemia
Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase patients...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3615898/ https://ncbi.nlm.nih.gov/pubmed/23569389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S35360 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|